General form of registration statement for all companies including face-amount certificate companies

Restatement of Previously Issued Financial Statements - Schedule of Restatement on Statement of Comprehensive Loss (Details)

v3.22.4
Restatement of Previously Issued Financial Statements - Schedule of Restatement on Statement of Comprehensive Loss (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (4,903,813) $ (5,196,438) $ (12,074,119) $ (9,611,146) $ (12,503,880) $ (6,636,660)
Comprehensive loss to MAIA Biotechnology, Inc. shareholder (4,951,314) $ (5,196,438) (12,125,765) $ (9,611,146)    
As Previously Reported            
Net loss attributable to MAIA Biotechnology, Inc. shareholders (5,031,843)   (12,202,149)      
Comprehensive loss to MAIA Biotechnology, Inc. shareholder (5,079,344)   (12,253,795)      
Adjustment            
Net loss attributable to MAIA Biotechnology, Inc. shareholders 128,030   128,030      
Comprehensive loss to MAIA Biotechnology, Inc. shareholder $ 128,030   $ 128,030